The novel adjuvant dmLT promotes dose sparing, @entity1200 and longevity of antibody responses to the inactivated polio vaccine in a XXXX model.

@entity12830 @entity9925 @entity19 @entity1701 @entity1200
UNASSIGNED: One option for achieving global polio eradication is to replace the oral @entity9925 vaccine (OPV), which has the risk of reversion to wild-type virulence, with the inactivated @entity9925 vaccine (IPV) vaccine. Adjuvants and alternate routes of immunization are promising options that may reduce antigen dose in IPV vaccinations, potentially allowing dose sparing and cost savings. Use of adjuvants and alternate routes of immunization could also help promote @entity1200 , potentially mimicking the protection against intestinal virus shedding seen with OPV. In the current study, we examined the impact of combining the novel adjuvant dmLT with trivalent IPV for dose sparing, induction of @entity1200 and increasing longevity of @entity1701 ( @entity1701 ) responses in a @entity19 model following either intradermal (ID) or intramuscular (IM) delivery. We found that non-adjuvanted ID delivery was not superior to IM delivery for fractional dose sparing, but was associated with development of @entity1200 . Vaccination with IPV+dmLT promoted serum anti- @entity1701 neutralizing antibodies with fractional IPV doses by either IM or ID delivery, achieving at least five-fold dose sparing above non-adjuvanted fractional doses. These responses were most noticeable with the @entity12830 component of the trivalent vaccine. dmLT also promoted germinal center formation and longevity of serum anti- @entity1701 neutralizing titers. Lastly, dmLT enhanced @entity1200 , as defined by fecal and intestinal anti- @entity1701 IgA secretion, when included in IPV immunization by ID or IM delivery. These studies demonstrate that dmLT is an effective adjuvant for either IM or ID delivery of IPV. Inclusion of dmLT in IPV immunizations allows antigen dose sparing and enhances @entity1200 and longevity of anti- @entity1701 responses.
